Diffusion-weighted MRI of estrogen receptor-positive, HER2-negative, node-negative breast cancer: association between intratumoral heterogeneity and recurrence risk

被引:36
|
作者
Kim, Jin You [1 ,2 ]
Kim, Jin Joo [1 ]
Hwangbo, Lee [1 ]
Lee, Ji Won [1 ]
Lee, Nam Kyung [1 ]
Nam, Kyung Jin [3 ]
Choo, Ki Seok [3 ]
Kang, Taewoo [4 ]
Park, Heeseung [4 ]
Son, Yohan [5 ]
Grimm, Robert [6 ]
机构
[1] Pusan Natl Univ Hosp, Med Res Inst, Dept Radiol, Busan, South Korea
[2] Pusan Natl Univ, Dept Radiol, Sch Med, 1-10 Ami Dong, Busan 602739, South Korea
[3] Pusan Natl Univ, Dept Radiol, Yangsan Hosp, Yangsan, South Korea
[4] Pusan Natl Univ Hosp, Busan Canc Ctr, Busan, South Korea
[5] Siemens Healthineers Ltd, Seoul, South Korea
[6] Siemens Healthcare GmbH, Erlangen, Germany
关键词
Diffusion magnetic resonance imaging; Breast neoplasms; Oncotype DX; Recurrence; Biomarkers; ADJUVANT SYSTEMIC THERAPY; ONCOTYPE-DX; AMERICAN-SOCIETY; EARLY-STAGE; TUMOR HETEROGENEITY; GENE-EXPRESSION; COEFFICIENT; CHEMOTHERAPY; WOMEN; SURVIVAL;
D O I
10.1007/s00330-019-06383-6
中图分类号
R8 [特种医学]; R445 [影像诊断学];
学科分类号
1002 ; 100207 ; 1009 ;
摘要
Objectives To investigate possible associations between quantitative apparent diffusion coefficient (ADC) metrics derived from whole-lesion histogram analysis and breast cancer recurrence risk in women with estrogen receptor (ER)-positive, human epidermal growth factor receptor 2 (HER2)-negative, node-negative breast cancer who underwent the Oncotype DX assay. Methods This retrospective study was conducted on 105 women (median age, 48 years) with ER-positive, HER2-negative, node-negative breast cancer who underwent the Oncotype DX test and preoperative diffusion-weighted imaging (DWI). Histogram analysis of pixel-based ADC data of whole tumors was performed, and various ADC histogram parameters (mean, 5th, 25th, 50th, 75th, and 95th percentiles of ADCs) were extracted. The ADC difference value (defined as the difference between the 5th and 95th percentiles of ADCs) was calculated to assess intratumoral heterogeneity. Associations between quantitative ADC metrics and the recurrence risk, stratified using the Oncotype DX recurrence score (RS), were evaluated. Results Whole-lesion histogram analysis showed that the ADC difference value was different between the low-risk recurrence (RS < 18) and the non-low-risk recurrence (RS >= 18; intermediate to high risk of recurrence) groups (0.600 x 10(-3) mm(2)/s vs. 0.746 x 10(-3) mm(2)/s, p < 0.001). Multivariate regression analysis demonstrated that a lower ADC difference value (< 0.559 x 10(-3) mm(2)/s; odds ratio [OR] = 5.998; p = 0.007) and a small tumor size (<= 2 cm; OR = 3.866; p = 0.012) were associated with a low risk of recurrence after adjusting for clinicopathological factors. Conclusions The ADC difference value derived from whole-lesion histogram analysis might serve as a quantitative DWI biomarker of the recurrence risk in women with ER-positive, HER2-negative, node-negative invasive breast cancer.
引用
收藏
页码:66 / 76
页数:11
相关论文
共 50 条
  • [41] Prediction of the MammaPrint Risk Group Using MRI Features in Women With Estrogen Receptor-Positive, HER2-Negative, and 1 to 3 Node-Positive Invasive Breast Cancer
    Kim, Hee Jeong
    Choi, Woo Jung
    Cha, Joo Hee
    Shin, Hee Jung
    Chae, Eun Young
    Kim, Hak Hee
    CLINICAL BREAST CANCER, 2024, 24 (02) : e80 - e90
  • [42] Intratumoral heterogeneity of Ki67 proliferation index outperforms conventional immunohistochemistry prognostic factors in estrogen receptor-positive HER2-negative breast cancer
    Zilenaite-Petrulaitiene, Dovile
    Rasmusson, Allan
    Besusparis, Justinas
    Valkiuniene, Ruta Barbora
    Augulis, Renaldas
    Laurinaviciene, Aida
    Plancoulaine, Benoit
    Petkevicius, Linas
    Laurinavicius, Arvydas
    VIRCHOWS ARCHIV, 2025, 486 (02) : 287 - 298
  • [43] Prospective trial of endocrine therapy alone in patients with estrogen receptor positive, HER2-negative, node-negative breast cancer: Results of the TAILORx low risk registry
    Sparano, J. A.
    Gray, R. J.
    Makower, D. F.
    Pritchard, K. I.
    Albain, K. S.
    Hayes, D. F.
    Geyer, C. E., Jr.
    Dees, E. C.
    Perez, E. A.
    Olson, J. A., Jr.
    Zujweski, J.
    Keane, M. M.
    Moreno, H. L. Gomez
    Reddi, R. P.
    Goggins, T. F.
    Mayer, I. A.
    Brufsky, A. M.
    Toppmeyer, D. L.
    Kaklamani, V. G.
    Atkins, J. N.
    Berenberg, J. L.
    Sledge, G. W., Jr.
    CANCER RESEARCH, 2016, 76
  • [44] Clinical considerations for estrogen receptor-negative/ progesterone receptor-positive/HER2-negative (ER-PR+HER2-) breast cancer
    Rala de Paula, Bruno Henrique
    Crocamo, Susanne
    Bines, Jose
    TRANSLATIONAL BREAST CANCER RESEARCH, 2023, 4
  • [45] T5 Is a New Molecular Predictor of Distant Recurrence in Estrogen Receptor-Positive, HER2-Negative Breast Cancer
    Filipits, M.
    Rudas, M.
    Jakesz, R.
    Dubsky, P.
    Singer, C. F.
    Dietze, O.
    Greil, R.
    Jelen, A.
    Sevelda, P.
    Freibauer, C.
    Fitzal, F.
    Mueller, V.
    Jaenicke, F.
    Schmidt, M.
    Koelbl, H.
    Rody, A.
    Kaufmann, M.
    Schroth, W.
    Schwab, M.
    Brauch, H.
    Weber, K.
    Feder, I.
    Hennig, G.
    Gehrmann, M.
    Gnant, M. F. X.
    CANCER RESEARCH, 2010, 70
  • [46] Ongoing unmet needs in treating estrogen receptor-positive/HER2-negative metastatic breast cancer
    Basaran, Gul A.
    Twelves, Chris
    Dieras, Veronique
    Cortes, Javier
    Awada, Ahmad
    CANCER TREATMENT REVIEWS, 2018, 63 : 144 - 155
  • [47] Neoadjuvant therapy in hormone Receptor-Positive/HER2-Negative breast cancer
    Cantini, Luca
    Trapani, Dario
    Guidi, Lorenzo
    Bielo, Luca Boscolo
    Scafetta, Roberta
    Koziej, Marcin
    Vidal, Laura
    Saini, Kamal S.
    Curigliano, Giuseppe
    CANCER TREATMENT REVIEWS, 2024, 123
  • [48] EndoPredict® in early hormone receptor-positive, HER2-negative breast cancer
    K. Almstedt
    S. Mendoza
    M. Otto
    M. J. Battista
    J. Steetskamp
    A. S. Heimes
    S. Krajnak
    A. Poplawski
    A. Gerhold-Ay
    A. Hasenburg
    C. Denkert
    M. Schmidt
    Breast Cancer Research and Treatment, 2020, 182 : 137 - 146
  • [49] Molecular classification of hormone receptor-positive HER2-negative breast cancer
    Jin, Xi
    Zhou, Yi-Fan
    Ma, Ding
    Zhao, Shen
    Lin, Cai-Jin
    Xiao, Yi
    Fu, Tong
    Liu, Cheng-Lin
    Chen, Yi-Yu
    Xiao, Wen-Xuan
    Liu, Ya-Qing
    Chen, Qing-Wang
    Yu, Ying
    Shi, Le-Ming
    Shi, Jin-Xiu
    Huang, Wei
    Robertson, John F. R.
    Jiang, Yi-Zhou
    Shao, Zhi-Ming
    NATURE GENETICS, 2023, 55 (10) : 1696 - +
  • [50] Neoadjuvant Therapy for weak receptor-positive/HER2-negative Breast Cancer
    Judith Lorenz, Kuenzell
    GEBURTSHILFE UND FRAUENHEILKUNDE, 2022, 82 (11) : 1124 - 1124